HOME >> BIOLOGY >> NEWS
New multiple myeloma treatment induced total remission in 33 percent of patients

A study, lead by Dr. Laura Rosiol, researcher of the Haematooncology Group of Hospital Clnic-IDIBAPS (Barcelona) in collaboration with Dr Joan Blade, researcher in the same group, administered alternately two drugs (Bortezomid and Dexamethasone) before conducting autologous bone marrow transplantations. The aim of this second phase trial was to assess the treatments overall response rate, its toxicity in patients, the possibility of recovery of innate stem cells, and the response kinetics which is calculated by measuring M-protein concentrations in serum and urine. M-protein is associated with myeloma presence.

This research work, conducted in the frame of the PETHEMA network, has been coordinated by Hospital Clnic de Barcelona and had the participation of eight more Spanish hospitals: Hospital Germans Trias i Pujol, Hospital Clnico Salamanca, Hospital de Sant Pau, Hospital Clnico de Madrid, Hospital La Princesa, Hospital 12 de Octubre and Hospital La Fe. A total of 40 patients between 41 and 65 years with newly diagnosed multiple myeloma participated in this study. All of them underwent six treatment cycles with a 10-day break between each, and were administered Bortezomid or Dexamethasone alternately.

This study has showed very relevant facts. The first notable fact is that there was a global reduction of M-protein concentration in both urine and plasma, reflecting a global reduction of tumour cells. Thus, a highly efficient anti-myeloma effect was observed, and the post autologous transplantation response index was favourable: a 94% response, one third of which (33%) was of complete response (CR) and 22% was a very good partial response (VGPR).

Another surprising result was the speed at which the effect was achieved i.e. the highest reduction in M-protein was detected within the first four treatment cycles. It should be mentioned that the first two cycles already caused an 82% reduction. These results set the base for furt
'"/>

Contact: Anna Ramon
comunicacio@clinic.ub.es
34-932-275-700
IDIBAPS - Institut d'Investigacions Biomdiques August Pi i Sunyer
4-Jun-2007


Page: 1 2

Related biology news :

1. Diverse genetic abnormalities lead to NF-κB activation in multiple myeloma
2. Research teams uncover risk genes for multiple sclerosis
3. First new multiple sclerosis gene found in 30 years
4. After a decades-long search, scientists identify new genetic risk factors for multiple sclerosis
5. Risk genes for multiple sclerosis uncovered
6. Obesity found to be a risk factor for multiple myeloma
7. Kaposi sarcoma arises independently from multiple cells
8. New collaborative research reveals chimpanzees can sustain multiple-tradition cultures
9. Testosterone may help men with multiple sclerosis
10. New imaging approach promises insights into multiple sclerosis
11. Study identifies multiple genetic risk factors for prostate cancer

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/20/2016)... and GENEVA, Dec, 20, 2016   Valencell ... sensor technology, and STMicroelectronics (NYSE: STM), a ... of electronics applications, announced today the launch of ... for biometric wearables that includes ST,s compact ... Valencell,s Benchmark™ biometric sensor system. Together, SensorTile ...
(Date:12/16/2016)... Research and Markets has announced the addition of the "Biometric ... to their offering. ... The biometric vehicle access system market, in terms of value, ... to 2021. The market is estimated to be USD 442.7 Million ... The growth of the biometric vehicle access system market is fueled ...
(Date:12/15/2016)... Calif. , Dec. 15, 2016   WaferGen ... publicly held genomics technology company, announced today that on ... Listing Qualifications Department of The Nasdaq Stock Market LLC ... closing bid price of WaferGen,s common stock had been ... Accordingly, WaferGen has regained compliance with Listing Rule 5550(a)(2) ...
Breaking Biology News(10 mins):
(Date:1/12/2017)... ... January 12, 2017 , ... After her brain cancer ... gave her only a few months to live. Now a paper publishing January ... Rosendahl’s disease and increased both the quantity and quality of her life: Adding ...
(Date:1/12/2017)... and Pune, India , January 12, 2017 ... Market by Type and End Users - Global Opportunity Analysis and Industry Forecast, 2014-2022," ... 2022 from $2,921 million in 2015, growing at a CAGR of 15.07% during the ... ... Allied Market Research Logo ...
(Date:1/11/2017)... ... January 11, 2017 , ... Phase 1 clinical trial ... of the investigational anti-cancer agent tucatinib (formerly ONT-380) against HER2+ breast cancer. The ... percent of these heavily pretreated patients saw clinical benefit from the drug, with ...
(Date:1/11/2017)... ... January 11, 2017 , ... Photonics industry and STEM ... are commending the U.S. Congress and President Obama for their recognition of the ... the American Innovation and Competitiveness Act (AICA). , The language of the act ...
Breaking Biology Technology:
Cached News: